Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
RUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Victoria E. Carr-Brendel, PhD, was elected to the Company's Board of Directors, effective May 22, 2025.
'We are delighted to welcome Dr. Carr-Brendel to Glucotrack's Board of Directors,' said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. 'With her exceptional leadership in medical devices and deep expertise in implantable technologies, she will be an invaluable addition to the Board as we advance our continuous blood glucose monitoring (CBGM) technology through clinical development and move closer to commercialization.'
Dr. Carr-Brendel currently serves as a member of the board of directors of Vicarious Surgical Inc. (NYSE: RBOT) since January 2023 and previously served from 2018 to 2024 as President and Group Vice President of Cochlear Implants at Sonova Group. Prior to that, she served as Chief Executive Officer of JenaValve Technology, Inc., a medical device company focused on developing minimally invasive transcatheter aortic valve repair systems for patients suffering from severe aortic valve disease. Previously, Dr. Carr-Brendel held various leadership roles at Boston Scientific, including overseeing the acquisition of Bayer's interventional radiology division in 2014. She started her career as a scientist in R&D with roles at Dexcom and Baxter Healthcare, amassing over forty patents and taking on increasingly senior business and management roles. She holds a BA in Biology from Monmouth College, an MS in Microbiology from Iowa State University, and a PhD in Microbiology and Immunology from the University of Illinois at Chicago.
'I am honored to be joining Glucotrack's Board of Directors at this pivotal time in the company's development,' said Victoria E. Carr-Brendel, PhD. 'The innovative CBGM has tremendous potential to address significant unmet needs for people with diabetes and enhance automated insulin delivery. I look forward to contributing to the Company as it works to achieve its strategic and clinical milestones.'
Glucotrack's CBGM is a long-term implantable system with no wearable component, designed for up to three years of continuous, accurate blood glucose monitoring, offering a more convenient and less intrusive glucose monitoring solution. The CBGM measures glucose directly from blood, unlike traditional continuous glucose monitoring systems which measure glucose from interstitial fluid. Thus, it aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements.
The Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information about Glucotrack's CBGM technology, visit glucotrack.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack's CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as 'anticipate', 'believe', 'expect', 'plan' and 'will' are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack's results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack's future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack's filings with the U.S. Securities and Exchange Commission (the 'SEC'), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.
Contacts:
Investor Relations:
[email protected]
Media:
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
16 minutes ago
- CNN
‘It is a whole different environment': Republicans revisit key Biden investigations with new momentum
The House Judiciary Committee is expected to interview former Hunter Biden special counsel David Weiss behind closed doors on Friday, two sources familiar with the interview told CNN, as part of a broader Republican effort to revisit previous probes into the Biden family that stalled last Congress but are gaining new momentum now that Republicans control both chambers of Congress and the White House. The scheduled interview, which could still be moved, would be the second time the Republican-led panel will interview Weiss about his work as Republicans continue to probe whether the investigation was hampered by political interference. Weiss has still never testified publicly about his six-year criminal probe into the president's son, which included three convictions, but was ultimately short-circuited as a result of the former president's unconditional pardon of his son. House Judiciary Republicans have long wanted to call Weiss, the Trump-appointed US attorney, back for questioning after his first closed-door interview in 2023. Committee Republicans were also able to finally secure interviews with two Department of Justice tax division prosecutors involved in the Hunter Biden probe who they had been aggressively pursuing for months, one of the sources familiar told CNN. The Justice Department is working with Weiss to provide access to documents he may need for his interview, a person briefed on the matter said. Any delays in getting access to documents would be a scheduling issue and the ability to have personnel who can oversee it, the person briefed on the matter said. It's not the only Biden investigation Republicans are reexamining that leans into a fresh political appetite with GOP control of Washington. House Oversight Chair James Comer is returning to his probe of the former president's mental fitness in an entirely new landscape after a recent book by CNN's Jake Tapper and Axios' Alex Thompson put Joe Biden's physical and mental decline back in the spotlight. Comer told CNN he is in the process of scheduling key interviews with Biden's White House physician, Dr. Kevin O'Connor, and other senior aides who had all rebuffed his efforts last Congress. Beyond the five initial interviews from Biden's orbit, the Republican Chairman told CNN he wants to look at the executive orders Biden signed in his last six months in office and use of the autopen. In the weeks immediately after Biden's disastrous 2024 debate performance that unraveled his presidential campaign and upended the Democratic party, Comer requested to interview Biden's doctor and subpoenaed three senior Biden aides to discuss their roles in the Biden White House, which never materialized. Now, Comer said in an interview with CNN, 'it is a whole different environment.' At the time of his 2024 interview requests, Comer's impeachment inquiry into the Biden family's business dealings had fallen apart and the Biden administration felt no incentive to comply with the House Oversight Committee. Probing Biden's decline now, Comer says, will be a lot easier than trying to convince his colleagues of an alleged Biden family foreign influence peddling scheme, which even Comer conceded was difficult to do, particularly in a minute or less on Fox News. Republicans failed to uncover evidence to support their core allegations against the president, and lacked the votes in their divided, narrow majority last Congress to impeach the president. 'The money laundering and the shell companies, the average American couldn't understand that. I mean, that was hard to understand,' Comer told CNN. 'You know, I did not do a good job explaining that.' But with his investigation into Biden's mental and physical decline, Comer said, 'people see a president that clearly is in decline. They saw it in the debate.' Democrats sought to dismantle the Republican-led 11 month impeachment inquiry into Biden last Congress at every turn. Comer told CNN that although those Democrats aren't jumping at the opportunity to cooperate now, he does not see them as being obstructive either. 'I take that as a step in the right direction,' he told CNN. Tapper and Thompson's book documents how Biden, his closest aides and his family forged ahead with the former president's doomed 2024 reelection bid despite signs of his physical and mental decline. In a previous statement to CNN, a Biden spokesman criticized the book, saying that evidence shows that 'he was a very effective president.' Former Democratic Rep. Dean Phillips, who launched a long-shot challenge to Biden and was outspoken about his concerns over the former president's age, told CNN he did not think there needed to be an investigation on Capitol Hill at this point into Biden's fitness as president. 'This case already went to trial, the jury of American voters convicted the party of the accused, and handed out the harshest political punishment possible-losing the single most consequential election in modern history,' Phillips told CNN. Instead, Phillips called on Biden to authorize his physician to disclose his health file and condition under oath. 'Only if the former president refuses, or if questioning uncovers possible criminal activity, should an investigation be initiated,' Phillips added. Biden was recently diagnosed with an 'aggressive form' of prostate cancer.
Washington Post
18 minutes ago
- Washington Post
McCarthy, Vikings value Jefferson's presence and leadership in offseason practices
EAGAN, Minn. — The Minnesota Vikings urged Justin Jefferson to fully participate in their offseason program, a commitment some established NFL stars aren't willing to make each spring. The sixth-year wide receiver was already a step ahead of the coaching staff. This is a critical offseason for Jefferson and the Vikings, breaking in a new quarterback in J.J. McCarthy , so he was planning to make his attendance a priority. 'It's definitely important to gain a little bit of a sight of what the new year is coming to look like, to build that connection with my teammates and especially with my quarterback,' Jefferson said after practice on Monday. 'It's definitely great to be out here early to kind of get into the feel.' These late spring practices, known in league parlance as organized team activities, are when the basic installation of the playbook begins, even though only the three-day minicamp next week is contractually mandated. It's also a prime opportunity to build that rhythm and trust between the quarterback and his receivers. 'He's a tremendous talent, tremendous leader, but his leadership really shows up when he's here,' said McCarthy, who accompanied Jefferson to a Timberwolves playoff game last month when they sat together in courtside seats. 'Just being able to get that chemistry building on and off the field has been invaluable.' Jefferson, whose 7,432 receiving yards are the most in league history through a player's first five seasons, said he doesn't concern himself with the style or tendencies of who's throwing. 'As long as the ball gets close to my face, I'm going to try to catch it,' he said. 'It doesn't matter how fast the ball is going, the spin of it or if it's coming from a lefty or a righty. My job is to catch the ball.' What's most important to Jefferson is the quarterback learning to adjust to his route-running preferences, with an exceptional stride length and side-to-side agility that helps set him apart. 'It's that timing, those reps,' McCarthy said. 'All of that has to be built up over time.' Which is why Jefferson being around all the time is so valuable. 'He's an energy igniter of the whole building, and I think he's come back with a purpose and a mindset,' coach Kevin O'Connell said. 'You hear his voice, you hear his interaction with teammates, and they just carry such a long way.' Not just for the quarterback. 'The guys in that locker room know, 'If this guy, one of the best in the world at what he does, is pushing himself in May and June, I sure as heck better be doing the same thing,'' O'Connell said. McCarthy, whose rookie season was spent entirely in the training room recovering from knee surgery, at least had some meaningful time in strategy meetings that helped him start to build the knowledge base in the offense even if he wasn't taking snaps on the field. 'I've been really surprised by some of the things that he does know. You're like, 'Man, we covered that in a 10-minute burst in Week 11 last year. How do you remember that?'' O'Connell said. 'And then there's some other things where you're like, 'Oh, I assumed he knew that.' So it's our job — baseline teaching and stacking days and layered learning so that we're constantly making him feel like he's growing but never comfortable.' Jefferson can see that too. 'He definitely has an arm, that's for sure. He can definitely zip it whenever he needs to,' he said, before recounting his advice to McCarthy at this stage of the offseason. 'Just let everything happen. Don't try to make the best play every single play.' ___ AP NFL:
Bloomberg
21 minutes ago
- Bloomberg
Trump Revokes Biden-Era Rule on Emergency Abortions in Hospitals
The Trump administration rescinded guidance put in place by former President Joe Biden that directed US hospitals to provide abortions on an emergency basis when they're medically necessary to stabilize patients. The guideline was established in July 2022 under the Emergency Medical Treatment and Labor Act, just weeks after the US Supreme Court overturned the Roe v. Wade decision that protected national abortion rights. It was enacted under the Centers for Medicare and Medicaid Services after women reported being turned away from hospitals while facing serious pregnancy complications, including severe bleeding.
